Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
| ▸ | CCNH | P51946 | 1/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908751 | 0.89 | ALDH1A1 (0.65) | LMNASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL3486176 | 0.81 | LMNA (0.80) | LMNASMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL15228509 | 0.78 | MCL1 (0.70) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL3782497 | 0.76 | PTGES2 (0.64) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL3534455 | 0.76 | FFAR1 (0.59) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL28728816 | 0.75 | CCR2 (0.57) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL19932328 | 0.74 | LMNA (0.66) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL19921881 | 0.74 | LMNA (0.66) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL1450639 | 0.73 | FFAR4 (0.57) | LMNASMN1; SMN2FFAR1CDK1CCNB1 | |
| SCHEMBL23200380 | 0.72 | KDM1A (0.79) | LMNASMN1; SMN2FFAR1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8198309-B2 | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198309-B2 | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2009038847-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | LMNA 3279/4885SMN1; SMN2 1990/4885FFAR1 185/4885 |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | LMNA 3279/4885SMN1; SMN2 1990/4885FFAR1 185/4885 |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CCR9, CCR1, CCR2 | LMNA 4305/4885SMN1; SMN2 1556/4885FFAR1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.